Cargando…
Novel Anti-fibrotic Therapies
Fibrosis is a major player in cardiovascular disease, both as a contributor to the development of disease, as well as a post-injury response that drives progression. Despite the identification of many mechanisms responsible for cardiovascular fibrosis, to date no treatments have emerged that have ef...
Autores principales: | McVicker, Benita L., Bennett, Robert G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449464/ https://www.ncbi.nlm.nih.gov/pubmed/28620300 http://dx.doi.org/10.3389/fphar.2017.00318 |
Ejemplares similares
-
A Selective PPARγ Modulator Reduces Hepatic Fibrosis
por: McVicker, Benita L., et al.
Publicado: (2020) -
Reduction in Obesity-Related Hepatic Fibrosis by SR1664
por: McVicker, Benita L., et al.
Publicado: (2023) -
Alcohol-induced tubulin post-translational modifications directly alter hepatic protein trafficking
por: Adhikari, Raghabendra, et al.
Publicado: (2023) -
Delirium—biomarkers and genetic variance
por: Stoicea, Nicoleta, et al.
Publicado: (2014) -
p38γ Activation and BGP (Biliary Glycoprotein) Induction in Primates at Risk for Inflammatory Bowel Disease and Colorectal Cancer—A Comparative Study with Humans
por: Talwar, Harvinder, et al.
Publicado: (2020)